Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston
The FIH study commenced in November 2021 and thus far, has treated 13 patients with symptomatically severe aortic stenosis (AS).
- The FIH study commenced in November 2021 and thus far, has treated 13 patients with symptomatically severe aortic stenosis (AS).
- The study will continue to enroll patients through 2022 and details of FIH can be found at ClinicalTrials.gov (Identifier: NCT05182307).
- By combining immediate and long-term benefits, DurAVRis perfectly suited for todays younger, more active patients, commented Wayne Paterson, Chief Executive Officer of Anteris Technologies.
- About Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.